Published in Semin Nucl Med on November 01, 2007
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia (2009) 1.52
Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging (2009) 1.23
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys (2009) 1.16
Is PET always an advantage versus planar and SPECT imaging? Eur J Nucl Med Mol Imaging (2008) 1.15
Molecular imaging of hypoxia. J Nucl Med (2011) 1.15
Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA). Eur J Nucl Med Mol Imaging (2009) 1.10
Imaging tumour hypoxia with positron emission tomography. Br J Cancer (2014) 1.09
Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging (2008) 1.07
Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer. J Oncol (2009) 1.06
Molecular imaging and targeted therapies. Biochem Pharmacol (2010) 1.05
Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol (2011) 1.02
From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol (2015) 0.99
Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A (2011) 0.98
Multimodality imaging of hypoxia in preclinical settings. Q J Nucl Med Mol Imaging (2010) 0.98
Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys (2009) 0.94
¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging (2012) 0.92
PET imaging with hypoxia tracers: a must in radiation therapy. Eur J Nucl Med Mol Imaging (2008) 0.92
Modeling tumor growth and treatment response based on quantitative imaging data. Integr Biol (Camb) (2010) 0.90
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
Non-invasive transdermal two-dimensional mapping of cutaneous oxygenation with a rapid-drying liquid bandage. Biomed Opt Express (2014) 0.89
Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using ¹⁸F-fluoromisonidazole positron emission tomographic imaging. Circ Cardiovasc Imaging (2014) 0.87
A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5). Nucl Med Biol (2012) 0.86
Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial. Radiat Oncol (2012) 0.85
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging (2013) 0.85
Microfluidics for positron emission tomography probe development. Mol Imaging (2010) 0.84
Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head Neck (2012) 0.83
Positron Emission Tomography Imaging of Hypoxia. PET Clin (2009) 0.82
Optimizing hypoxia detection and treatment strategies. Semin Nucl Med (2015) 0.81
Positron Emission Tomography in Breast Cancer. Diagnostics (Basel) (2015) 0.81
Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. Cancer Imaging (2010) 0.81
PET-specific parameters and radiotracers in theoretical tumour modelling. Comput Math Methods Med (2015) 0.80
Usefulness of FMISO-PET for glioma analysis. Neurol Med Chir (Tokyo) (2013) 0.80
Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI. NMR Biomed (2012) 0.80
Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. Am J Nucl Med Mol Imaging (2015) 0.80
(18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. Eur J Nucl Med Mol Imaging (2016) 0.80
Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging (2014) 0.79
PET probes beyond (18)F-FDG. J Biomed Res (2014) 0.79
Frontiers of Biomedical Imaging Science 2009: workshop report and research opportunities. Cancer Res (2009) 0.78
Vascular incontinence: incontinence in the elderly due to ischemic white matter changes. Neurol Int (2012) 0.77
Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nat Rev Clin Oncol (2016) 0.77
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin (2016) 0.76
Molecular imaging of pulmonary cancer and inflammation. Proc Am Thorac Soc (2009) 0.76
Imaging biomarkers or biomarker imaging? Pharmaceuticals (Basel) (2014) 0.76
[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging (2017) 0.76
Molecular mechanisms of hypoxia in cancer. Clin Transl Imaging (2017) 0.75
Stroma targeting nuclear imaging and radiopharmaceuticals. Int J Mol Imaging (2012) 0.75
Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer. EJNMMI Phys (2016) 0.75
Synthesis and Biological Evaluation of Iodoglucoazomycin (I-GAZ), an Azomycin-Glucose Adduct with Putative Applications in Diagnostic Imaging and Radiotherapy of Hypoxic Tumors. ChemMedChem (2016) 0.75
Molecular imaging-its current role in cancer. QJM (2015) 0.75
Assessment of the Tumor Redox Status in Head and Neck Cancer by 62Cu-ATSM PET. PLoS One (2016) 0.75
Molecular imaging of hypoxia in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2015) 0.75
(18)F-FDG PET as novel imaging biomarker for disease progression after ablation therapy in colorectal liver metastases. Eur J Nucl Med Mol Imaging (2017) 0.75
Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer. Cancer Sci (2015) 0.75
Imaging radiation response in tumor and normal tissue. Am J Nucl Med Mol Imaging (2015) 0.75
Towards multidimensional radiotherapy: key challenges for treatment individualisation. Comput Math Methods Med (2015) 0.75
Integrating Imaging Data into Predictive Biomathematical and Biophysical Models of Cancer. ISRN Biomath (2012) 0.75
Multimodality Imaging in Tumor Angiogenesis: Present Status and Perspectives. Int J Mol Sci (2017) 0.75
Hypoxia in cervical cancer: from biology to imaging. Clin Transl Imaging (2017) 0.75
Hypoxia imaging and radiotherapy: bridging the resolution gap. Br J Radiol (2017) 0.75
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods (2012) 2.46
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol (2012) 1.95
Oncology health information quality on the Internet: a multilingual evaluation. Ann Surg Oncol (2011) 1.73
Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med (2006) 1.69
The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia (2009) 1.64
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A (2003) 1.56
Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol (2006) 1.56
The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res (2007) 1.53
CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor. J Biol Chem (2004) 1.45
Impact of ¹⁸F-FDG-PET in decision making for liver metastectomy of colorectal cancer. ANZ J Surg (2011) 1.39
Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med (2006) 1.38
Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med (2006) 1.34
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 1.33
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J Biol Chem (2006) 1.30
Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer Res (2005) 1.28
The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene (2004) 1.28
Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer (2002) 1.27
Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest (2007) 1.26
Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol (2011) 1.23
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem (2004) 1.23
Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res (2012) 1.21
Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg (2002) 1.20
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci U S A (2003) 1.20
Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res (2005) 1.16
Global trends in hybrid imaging. Radiology (2010) 1.15
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A (2005) 1.14
Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia (2007) 1.12
Antibodies in oncology. N Biotechnol (2011) 1.09
Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy. Eur J Nucl Med Mol Imaging (2005) 1.08
Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother (2002) 1.08
The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J (2005) 1.07
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A (2009) 1.07
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res (2009) 1.06
HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res (2006) 1.05
Positron emission tomography and epilepsy. Mol Imaging Biol (2002) 1.04
Positron emission tomography and molecular imaging of the prostate: an update. BJU Int (2006) 1.03
Three-dimensional structures of carbohydrate determinants of Lewis system antigens: implications for effective antibody targeting of cancer. Immunol Cell Biol (2005) 1.03
Functional imaging of intratumoral hypoxia. Mol Imaging Biol (2004) 1.01
Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog (2012) 1.00
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res (2005) 1.00
Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res (2005) 1.00
Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging (2005) 0.99
Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci (2007) 0.99
Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation. Cancers (Basel) (2011) 0.98
Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol (2002) 0.98
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2011) 0.97
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int (2005) 0.97
Radiation dose to PET technologists and strategies to lower occupational exposure. J Nucl Med Technol (2005) 0.97
Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother Radiopharm (2008) 0.96
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun (2007) 0.96
Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells. ACS Nano (2007) 0.96
A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun (2007) 0.96
High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol (2009) 0.96
Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin Cancer Res (2007) 0.95
Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med (2006) 0.95
Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. J Mol Biol (2004) 0.94
A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. Growth Factors (2009) 0.93
Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS One (2012) 0.93
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer (2009) 0.92
Targeting of cancer cells using click-functionalized polymer capsules. J Am Chem Soc (2010) 0.92
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. J Thorac Oncol (2007) 0.91
Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. J Cell Sci (2011) 0.91
Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU Int (2006) 0.91
A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma. Cancer Sci (2006) 0.91
Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. Eur J Pharmacol (2011) 0.91
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. Urol Oncol (2009) 0.90
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother (2009) 0.90
Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys (2012) 0.90
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate (2009) 0.89
Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008. Clin Cancer Res (2013) 0.88
Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol (2012) 0.88
Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci (2003) 0.88
Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy. Radiother Oncol (2011) 0.87
Benign ectopic multinodular thyroid tissue in the submandibular region with a coexistent normotopic multinodular thyroid gland harboring papillary thyroid cancer. Clin Nucl Med (2010) 0.86
Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses. Hybrid Hybridomics (2003) 0.86
Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. J Immunol (2004) 0.85
Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation. J Med Imaging Radiat Oncol (2011) 0.85
Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. J Cell Mol Med (2009) 0.84
Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model. Mol Cancer Ther (2003) 0.84
PET in prostate and bladder tumors. Semin Nucl Med (2012) 0.84
Functional imaging of renal cell carcinoma. Nat Rev Urol (2010) 0.84
Monoclonal antibody dose determination and biodistribution into solid tumors. Ther Deliv (2011) 0.83
Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules. ACS Nano (2012) 0.83
Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma. Mol Imaging Biol (2006) 0.83
Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806. J Nucl Med (2010) 0.83
Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Eur Radiol (2013) 0.83
Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. Ann Surg Oncol (2014) 0.82
Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. Int J Urol (2007) 0.82
Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases. J Nucl Med (2012) 0.82
Fully automated synthesis and coupling of [(18) F]FBEM to glutathione using the iPHASE FlexLab module. J Labelled Comp Radiopharm (2014) 0.82
A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody. PLoS One (2009) 0.82
Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res (2012) 0.82
Macromolecule functionalization of disulfide-bonded polymer hydrogel capsules and cancer cell targeting. ACS Nano (2012) 0.82
Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder. Psychiatry Res (2010) 0.81
Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study. Acta Oncol (2013) 0.81
Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers. Biochemistry (2011) 0.81
Ligand binding induces a conformational change in epidermal growth factor receptor dimers. Growth Factors (2012) 0.81
Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem Biol (2011) 0.81
Efficiency of T-cell costimulation by CD80 and CD86 cross-linking correlates with calcium entry. Immunology (2009) 0.81